Found 45 clinical trials
C-Reactive Protein/Albumin Ratio and Acne Vulgaris
This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study …
- 0 views
- 23 Apr, 2025
- 3 locations
Skin Toxicity by Oncological Therapies (SKINTOX)
This is a multicenter, retrospective and prospective observational study. The project involves the collection of clinical data of patients treated with oncological therapies, to evaluate skin toxicities related to oncological treatment.
- 0 views
- 15 Nov, 2021
- 20 locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)
Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …
- 0 views
- 04 Dec, 2020
- 126 locations
Exercise and Tumor Blood Flow in Breast Cancer Patients
It is hypothesized and expected that acute exercise increases tumor blood flow, which could plausibly increase the efficacy of cancer treatment.
- 0 views
- 05 Aug, 2020
NoIAmNot Trial
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 21 Feb, 2023
enrolling Trial
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 22 Feb, 2023
COPD-ICU Multicentre Prospective Observational Register (COPD-ICU)
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 21 Feb, 2023
second sync
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 21 Feb, 2023
scrumsecond sync
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 22 Feb, 2023
- 1 location
scrumsecond sync
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 25 Feb, 2023